1. 国家自然科学基金委员会，青年科学基金项目，82102363，干扰素诱导跨膜蛋白抑制SARS-CoV-2流行变异株感染侵入的分子机制研究，2022-01-01 至2024-12-31，30万元，已结题，主持；

2. 北京市医院管理中心青年人才培养“青苗”计划，QML20211801，溶酶体巯基还原酶GILT抑制新型冠状病毒流行变异株侵入的机制研究，2022/01-2023/12，12万元，已结题，主持

3. 北京市教委科研计划一般项目，KM201910025003，冠状病毒NL63利用不同种属ACE2受体感染宿主细胞的机制研究，2019/01-2021/12，15万元，已结题，主持；

4.  国家重点研发计划，2023YFC2306003，重要病毒疫苗免疫保护效果机制研究，2023/12-2026/11，284万元，在研，骨干；

5.  国家重点研发计划，2023YFC3043500，新冠疫情临床监测预警体系构建与应用研究，2023/10-2025/09，200万元，在研，参与；

6. 国家自然科学基金委员会，面上项目，81971916，泛素化修饰介导的干扰素诱导跨膜蛋白3双向调控包膜病毒感染侵入机制的研究，2020/01-2023/12，55万元，已结题，参与；

(1)  Chen Danying#., Li Xinglin#.,Hao Xiaohua#., Qiu Yaruo#., Song Yanjun., Sun Hui., LiuYongmei., Du Juan., Zhang Yuanyuan., Xiao Fan., Song Chuan., Yan Yonghong.,Song Rui., Wang Xi*., Zhao Xuesen*., Jin Ronghua*.(2023).Reduced neutralization and Fc effector function to Omicron subvariants in serafrom SARS-CoV-1 survivors after two doses of CoronaVac plus one dose subunitvaccine. J Med Virol, 95(10), e29136. doi:10.1002/jmv.29136 

(2)  Chen Danying^#., Hou Zhifei^#.,Jiang Dong^#., Zheng Mei^#., Li Guoli., Zhang Yue., LiRui., Lin Hanxin., Chang Jinhong., Zeng Hui., Guo Ju-Tao^*., ZhaoXuesen^*.(2019). GILT restricts the cellularentry mediated by the envelope glycoproteins of SARS-CoV, Ebola virus and Lassafever virus. Emerging microbes & infections 2019;8(1):1511-1523.doi:10.1080/22221751.2019.1677446 

(3)  Liu Yongmei#., Chen Danying#.,Wang Yuanyuan#., Li Xinglin., Qiu Yaruo., Zheng Mei., Song Yanjun.,Li Guoli., Song Chuan., Liu Tingting., Zhang Yuanyuan., Guo Ju-Tao., Lin Hanxin*.,Zhao Xuesen*. (2023). Characterization of CCoV-HuPn-2018 spikeprotein-mediated viral entry. J Virol, Epub ahead of print:e0060123.doi:10.1128/jvi.00601-23 

(4)  Yu Minghang#., Chen Danying#.,Tang Xiaomeng#., Zhang Yuanyuan#., Liang Pu., XiongYang., Li Rui., Song Rui., Chen Xiaoyou., Zhao Xuesen*., Wang Xi*.,Jin Ronghua*.(2023). Evaluation of a high-sensitivity SARS-CoV-2antigen test on the fully automated light-initiated chemiluminescentimmunoassay platform. Clin Chem Lab Med, 61(6), 1123-1130.doi:10.1515/cclm-2022-1039 

(5)  Li Jiarui#., Du Pengcheng#.,Yang Lijiang#., Zhang Ju#., Song Chuan#.,Chen Danying#., Song Yangzi., Ding Nan., Hua Mingxi., HanKai., Song Rui., Xie Wen., Chen Zhihai., Wang Xianbo., Liu Jingyuan., XuYanli., Gao Guiju., Wang Qi., Pu Lin., Di Lin., Li Jie., Yue Jinglin., HanJunyan., Zhao Xuesen., Yan Yonghong., Yu Fengting., Wu Angela R., Zhang Fujie*.,Gao Yi Qin*., Huang Yanyi*., Wang Jianbin*.,Zeng Hui*., Chen Chen*.(2022). Two-step fitness selectionfor intra-host variations in SARS-CoV-2. Cell reports 2022 0111;38(2):110205. doi:10.1016/j.celrep.2021.110205 

(6)  Junyan Han#., Ning Zhang#.,DanyingChen#.,Yuhuan Gong#., Guoli Li#., Yaxian Kong., Lin Pu., ChenChen., Jingyuan Liu., Qi Wang., Ju Zhang., Xuesen Zhao., Juan Du., Kai Han.,Chuan Song., Linghang Wang., Mingxi Hua., Yu Hao., Rui Song., Yangzi Song.,Fengting Yu., Siyuan Yang., Haofeng Xiong., Wei Zhang., George F Gao*.,Fujie Zhang*., Ang Li*., Hui Zeng*., Yuhai Bi*.(2021).Distinct durability of IgM/IgG antibody responses in COVID-19 patients withdiffering severity. Science China. Life sciences,2022 01;65(1):223-226doi:10.1007/s11427-020-1947-y 

(7)  Ju Zhang#, Nan Ding#,Lili Ren#, Rui Song#, Danying Chen#,Xuesen Zhao, Budong Chen, Junyan Han, Jiarui Li, Yangzi Song, Lin Di, Kai Han,Fengting Yu, Ruming Xie, Zhihai Chen, Wen Xie, Jingyuan Liu, Shan Cen, YuhaiBi, Angela R Wu*, Fujie Zhang*, Chen Chen*,Hui Zeng*, COVID-19 reinfection in the presence of neutralizing antibodies, NationalScience Review, 2021, 8 (4) :nwab006, https://doi.org/10.1093/nsr/nwab006 

(8)  Zhao Xuesen#,*., ChenDanying#., Szabla Robert., Zheng Mei., Li Guoli., DuPengcheng., Zheng Shuangli., Li Xinglin., Song Chuan., Li Rui., Guo Ju-Tao.,Junop Murray., Zeng Hui., Lin Hanxin.(2020). Broad andDifferential Animal Angiotensin-Converting Enzyme 2 Receptor Usage bySARS-CoV-2. J Virol, 94(18), undefined.doi:10.1128/JVI.00940-20  

(9)  Zhao Xuesen#,*., ZhengShuangli#., Chen Danying#., Zheng Mei., LiXinglin., Li Guoli., Lin Hanxin., Chang Jinhong., Zeng Hui., Guo Ju-Tao*.(2020).LY6E Restricts Entry of Human Coronaviruses, IncludingCurrently Pandemic SARS-CoV-2. Journal of virology 2020 0831;94(18). doi:10.1128/JVI.00562-20 

(10)  Zheng Mei#., Zhao Xuesen#,*.,Zheng Shuangli#., Chen Danying#., DuPengcheng., Li Xinglin., Jiang Dong., Guo Ju-Tao., Zeng Hui*., LinHanxin*.(2020). Bat SARS-Like WIV1 coronavirus uses the ACE2 ofmultiple animal species as receptor and evades IFITM3 restriction via TMPRSS2activation of membrane fusion. Emerging microbes & infections 2020Dec;9(1):1567-1579 . doi:10.1080/22221751.2020.1787797